Shire Finds Another Orphan Opportunity, Licenses Acceleron's DMD Drug
This article was originally published in The Pink Sheet Daily
Executive SummaryThe deal gives the Irish pharma rights outside the U.S. and Canada to an entire family of proteins that address muscle disorders.
You may also be interested in...
Launched in fall 2012 via a partnership between Amgen and Kleiner Perkins Caufield & Byers, the Bay Area biotech has three subsidiary companies housing six biologic assets that used to belong to Amgen. With two financing rounds this year totaling $58.5 million, three candidates are slated to enter the clinic by 2015.